Quantcast

Fosamax Lawsuits: Bernstein Liebhard LLP Notes Upcoming Monthly Management Conference in New Jersey Fosamax Litigation

March 28, 2013

The Firm continues to investigate Fosamax lawsuits on behalf of individuals who allegedly suffered Fosamax femur fractures due to long-term use of the drug.

New York, New York (PRWEB) March 28, 2013

Fosamax lawsuits continue to move forward in a consolidated litigation now underway in New Jersey Superior Court, Bernstein Liebhard LLP reports. According to the calendar posted on the Court´s website, the Fosamax litigation´s next monthly management conference has been scheduled for April 10th at 10:00 a.m. All of the lawsuits pending in the New Jersey litigation allege long-term use of Fosamax caused patients to develop serious side effects, including Fosamax femur fractures. Bernstein Liebhard LLP is actively filing Fosamax lawsuits in the New Jersey proceeding. (In re: Fosamax Litigation, No. 282, N.J. Super. Ct)

“We continue to hear from women who allegedly suffered femur fractures and other serious complications following long-term use of Fosamax. We are pleased to see this litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Fosamax femur fractures.

Fosamax Femur Fractures

Fosamax lawsuits involving femur fracture allegations have been mounting since October 2010, when the U.S. Food & Drug Administration (FDA) cautioned that some studies had indicated patients taking bisphosphonates for osteoporosis were at heightened risk for atypical femur fractures. Among other things, the FDA advised doctors to consider periodic reevaluation of bisphosphonate therapy, particularly in patients who have been treated for over 5 years.*

Court records indicate that more than 2,000 Fosamax femur fracture claims are currently pending in New Jersey Superior Court. Another 850 lawsuits involving Fosamax and femur fractures have been filed in a federal multidistrict litigation established in U.S. District Court, District of New Jersey. (In re: Fosamax (Alendronate Sodium) Products Liability Litigation (No. II) – MDL No. 2243) Earlier this month, the first Fosamax femur facture claim to go to trial in the New Jersey state litigation was declared a mistrial, after the plaintiff became ill. Court documents do not indicate when that case might be rescheduled for trial. (Su v. Merck Sharp & Dohme Corp., case number ATL-L-0789-11)

Victims of alleged Fosamax femur fractures could be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages. A wealth of information regarding Fosamax lawsuits is available by visiting Bernstein Liebhard LLP´s website. To arrange for a free case review, please contact Bernstein Liebhard LLP at (877) 779-1414.

*fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229171.htm

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs´ Hot List,” recognizing the top plaintiffs´ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info(at)consumerinjurylawyers(dot)com

http://www.consumerinjurylawyers.com

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebfosamax-lawsuits/fosamax-femur-fractures/prweb10578098.htm


Source: prweb



comments powered by Disqus